These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 19589091

  • 1. Novel inhibitors of the PI3K family.
    Carnero A.
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1265-77. PubMed ID: 19589091
    [Abstract] [Full Text] [Related]

  • 2. PTEN, more than the AKT pathway.
    Blanco-Aparicio C, Renner O, Leal JF, Carnero A.
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [Abstract] [Full Text] [Related]

  • 3. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 4. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C, Sellers WR.
    Oncogene; 2008 Sep 18; 27(41):5511-26. PubMed ID: 18794885
    [Abstract] [Full Text] [Related]

  • 5. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR.
    Expert Rev Mol Diagn; 2010 Jan 18; 10(1):75-87. PubMed ID: 20014924
    [Abstract] [Full Text] [Related]

  • 6. Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs.
    Shah BH, Neithardt A, Chu DB, Shah FB, Catt KJ.
    J Cell Physiol; 2006 Jan 18; 206(1):47-57. PubMed ID: 15920762
    [Abstract] [Full Text] [Related]

  • 7. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells.
    Chen KC, Zhou Y, Zhang W, Lou MF.
    Mol Vis; 2007 Mar 14; 13():374-87. PubMed ID: 17392688
    [Abstract] [Full Text] [Related]

  • 8. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P.
    Curr Opin Pharmacol; 2008 Aug 14; 8(4):393-412. PubMed ID: 18721898
    [Abstract] [Full Text] [Related]

  • 9. RAS: target for cancer therapy.
    Saxena N, Lahiri SS, Hambarde S, Tripathi RP.
    Cancer Invest; 2008 Nov 14; 26(9):948-55. PubMed ID: 18798058
    [Abstract] [Full Text] [Related]

  • 10. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ.
    J Med Chem; 2008 Sep 25; 51(18):5522-32. PubMed ID: 18754654
    [Abstract] [Full Text] [Related]

  • 11. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.
    Expert Opin Investig Drugs; 2009 Sep 25; 18(9):1333-49. PubMed ID: 19678801
    [Abstract] [Full Text] [Related]

  • 12. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
    Lin J, Adam RM, Santiestevan E, Freeman MR.
    Cancer Res; 1999 Jun 15; 59(12):2891-7. PubMed ID: 10383151
    [Abstract] [Full Text] [Related]

  • 13. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 15; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 14. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
    Olsen BB, Bjørling-Poulsen M, Guerra B.
    Int J Biochem Cell Biol; 2007 Aug 15; 39(1):227-37. PubMed ID: 17018259
    [Abstract] [Full Text] [Related]

  • 15. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK.
    IUBMB Life; 2003 Mar 15; 55(3):117-26. PubMed ID: 12822887
    [Abstract] [Full Text] [Related]

  • 16. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
    Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ.
    Curr Opin Investig Drugs; 2005 Dec 15; 6(12):1250-8. PubMed ID: 16370391
    [Abstract] [Full Text] [Related]

  • 17. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G.
    Methods Mol Biol; 2012 Dec 15; 795():1-34. PubMed ID: 21960212
    [Abstract] [Full Text] [Related]

  • 18. The PKB/AKT pathway in cancer.
    Carnero A.
    Curr Pharm Des; 2010 Jan 15; 16(1):34-44. PubMed ID: 20214616
    [Abstract] [Full Text] [Related]

  • 19. Between bench and bed side: PI3K inhibitors.
    Paz-Ares L, Carnero A.
    Curr Mol Pharmacol; 2010 Jun 15; 3(2):79-90. PubMed ID: 20302563
    [Abstract] [Full Text] [Related]

  • 20. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E, Spinelli M, Vanoni M.
    Expert Opin Ther Pat; 2012 Nov 15; 22(11):1263-87. PubMed ID: 23009088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.